Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proof-of-concept ("POC") trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer ("NSCLC") in China.

4 Sep 2015

New NIH grants support research that combines DNA sequence information and electronic medical records

A dozen awards from the National Institutes of Health will support research that incorporates DNA sequence information into electronic medical records. The goal of research conducted by the Electronic Medical Records and Genomics (eMERGE) network is to better understand the genomic basis of disease and to tailor medical care to individual patients based on their genomic differences.

2 Sep 2015

Mayo Clinic study identifies benchmarks for postsurgical outcomes in patients with colorectal cancer

About 20 percent of colorectal cancer patients have cancers that have spread (metastasized) beyond the colon at the time of their diagnosis. The liver is the most common site for these metastases. The approach to treating primary tumors within the colon and metastatic tumors in the liver continues to evolve; however, it typically involves chemotherapy plus surgical removal (resection) of both types of tumors. However, experts continue to debate whether surgical resection of primary tumors and metastatic tumors should be performed at the same time (synchronously) or in separate operations (sequentially).

1 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Moffitt researchers hope to improve pancreatic cancer survival rates by developing blood test to identify IPMNs

Pancreatic cancer is the fourth most common cause of cancer-related death in the United States and has a 5-year survival rate of only 6 percent, which is the lowest rate of all types of cancer according to the American Cancer Society.

29 Aug 2015

Researchers identify druggable target to potentially root out colon cancer, end relapse

Researchers targeting colorectal cancer stem cells - the root cause of disease, resistance to treatment and relapse - have discovered a mechanism to mimic a virus and potentially trigger an immune response to fight the cancer like an infection.

28 Aug 2015

Obesity raises Lynch syndrome CRC risk

Obesity increases the risk of colorectal cancer in patients with Lynch syndrome, research indicates, but daily aspirin use may combat this excess risk.

27 Aug 2015

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells' ability to avoid detection and destruction by the immune system.

27 Aug 2015

New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

About 3% of colorectal cancers are due to Lynch syndrome, an inherited cancer susceptibility syndrome that predisposes individuals to various cancers. Close blood relatives of patients with Lynch syndrome have a 50% chance of inheritance. The role that PMS2 genetic mutations play in Lynch syndrome has been underestimated in part due to technological limitations.

27 Aug 2015

Longer-lasting colonoscopies associated with lower cancer rates

If a colonoscopy seems like the type of thing you'd like to get done with quickly, think again. Research by a Veterans Affairs team has confirmed that longer-lasting colonoscopies are associated with lower cancer rates.

26 Aug 2015

Study reveals how inflammation triggers colon cancer cells to metastasize

A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois, M.D., Ph.D., has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.

26 Aug 2015

Researchers find way to screen blood samples to detect presence of precancerous polyps in the colon

Canadian researchers have found a way to screen blood samples for molecular traces that indicate the presence of precancerous polyps in the colon, a key warning sign for colon cancer. Their results, published this week in the journal Biomedical Optics Express, from The Optical Society, may yield a cheaper and less invasive initial screening test for colon cancer that could complement colonoscopy, though further clinical trials will need to demonstrate the safety and effectiveness of the blood test before it is routinely used.

25 Aug 2015

Three medical oncologists to receive ESMO's acclaimed awards

The European Society for Medical Oncology, the leading European professional organisation for advancing medical oncology, announced today the three exceptional medical oncologists who will receive its acclaimed awards.

24 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

PHD1 inhibition may have therapeutic potential for colorectal cancer

Scientists at VIB and KU Leuven have shown that blocking the PHD1 oxygen sensor hinders the activation of p53, a transcription factor that aids colorectal cancer (CRC) cells in repairing themselves and thus resisting chemotherapy. Chemotherapy resistance remains a major clinical issue in the treatment of CRC. These findings indicate that PHD1 inhibition may have valuable therapeutic potential. The study was published in the leading medical journal EMBO Molecular Medicine, which features molecular biology-driven research.

19 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

VolitionRx reports net loss of $1.9 million for second quarter 2015

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the second quarter ended June 30, 2015.

11 Aug 2015

CSN6 protein linked to poor survival among patients with colorectal cancer

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.

11 Aug 2015

Penn research reveals additional pathway for origin of colon cancer

Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process.

6 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

New NIH grants support research that combines DNA sequence information and electronic medical records

Mayo Clinic study identifies benchmarks for postsurgical outcomes in patients with colorectal cancer

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Moffitt researchers hope to improve pancreatic cancer survival rates by developing blood test to identify IPMNs

Researchers identify druggable target to potentially root out colon cancer, end relapse

Obesity raises Lynch syndrome CRC risk

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

Longer-lasting colonoscopies associated with lower cancer rates

Study reveals how inflammation triggers colon cancer cells to metastasize

Researchers find way to screen blood samples to detect presence of precancerous polyps in the colon

Three medical oncologists to receive ESMO's acclaimed awards

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

PHD1 inhibition may have therapeutic potential for colorectal cancer

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

VolitionRx reports net loss of $1.9 million for second quarter 2015

CSN6 protein linked to poor survival among patients with colorectal cancer

Penn research reveals additional pathway for origin of colon cancer

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in